Cargando…
Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer
HER-2 and the vascular endothelial factor receptor (VEGF) represent validated targets for the therapy of multiple tumor types and inhibitors of these receptors have gained increasing importance in the clinic. In this context, novel bioactive agents associated with better therapeutic outcomes and imp...
Autores principales: | Foy, Kevin C., Miller, Megan J., Moldovan, Nicanor, Bozanovic, Tatjana, Carson, William E., Kaumaya, Pravin T. P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494615/ https://www.ncbi.nlm.nih.gov/pubmed/23170249 http://dx.doi.org/10.4161/onci.21057 |
Ejemplares similares
-
Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo
por: Foy, Kevin C., et al.
Publicado: (2012) -
Correction to: Foy KC, Miller MJ, Moldovan N, Carson III WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 2012; 1:1048–1060
por: Foy, Kevin C., et al.
Publicado: (2013) -
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
por: Arai, Roberto J., et al.
Publicado: (2018) -
Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2016) -
Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)
por: Overholser, Jay, et al.
Publicado: (2015)